Literature DB >> 33195651

Dehydrated patient without clinically evident cause: A case report.

Federica Palladino1, Maria Cristina Fedele1, Marianna Casertano1, Laura Liguori1, Tiziana Esposito1, Stefano Guarino1, Emanuele Miraglia Del Giudice1, Pierluigi Marzuillo2.   

Abstract

BACKGROUND: Patients affected by cystic fibrosis can present with metabolic alkalosis such as Bartter's syndrome. In this case report we want to underline this differential diagnosis and we aimed focusing on the suspect of cystic fibrosis, also in case of a negative newborn screening. CASE
SUMMARY: In a hot August -with a mean environmental temperature of 36 °C- an 8-mo-old female patient presented with severe dehydration complicated by hypokalemic metabolic alkalosis, in absence of fever, diarrhea and vomiting. Differential diagnosis between cystic fibrosis and tubulopathies causing metabolic alkalosis (Bartter's Syndrome) was considered. We started intravenous rehydration with subsequent improvement of clinical conditions and serum electrolytes normalization. We diagnosed a mild form of cystic fibrosis (heterozygous mutations: G126D and F508del in the cystic fibrosis transmembrane conductance regulator gene). The trigger factor of this condition had been heat exposure.
CONCLUSION: When facing a patient with hypokalemic metabolic alkalosis, cystic fibrosis presenting with Pseudo-Bartter's syndrome should be considered in the differential diagnosis, even if the newborn screening was negative. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Children; Cystic fibrosis; Dehydration; Heat exposure; Metabolic alkalosis; Pseudo-Bartter syndrome

Year:  2020        PMID: 33195651      PMCID: PMC7642545          DOI: 10.12998/wjcc.v8.i20.4838

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


Core Tip: We report a case of cystic fibrosis presenting with hypokalemic metabolic alkalosis caused by dehydration after heat exposure. We diagnosed a mild form of cystic fibrosis. In particular we wanted focusing on differential diagnosis between cystic fibrosis and Bartter’s Syndrome. We want to highlight that atypical forms of cystic fibrosis could escape to neonatal screening and prompt diagnosis is important for prognosis.

INTRODUCTION

Cystic fibrosis (CF) is a monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on chromosome 7. CF is complex and greatly variable in clinical expression[1]. Airways, pancreas, male genital system, intestine, liver, bone, and kidney are involved. CFTR-related disorders are conditions determined by mutations in the CFTR gene but not giving the usual CF clinical picture. They are often mild form of CF and their clinical manifestations are limited to a single district and include episodes of recurrent pancreatitis or isolated bilateral bronchiectasis. Males can manifest bilateral agenesis of the vas deferens with no digestive or respiratory involvement[2]. Both CF and CFTR-related disorders can present metabolic alkalosis, such Bartter’s syndrome (BS). In this case report we want to underline differential diagnosis between cystic fibrosis and tubulopathies causing metabolic alkalosis (such as BS). Moreover, we aimed focusing on the possibility of suspect diagnosis of cystic fibrosis, nevertheless a negative newborn screening.

CASE PRESENTATION

Chief complaints

In a hot August –with a mean environmental temperature of 36 °C– an 8-mo-old female patient come to our observation because of somnolence and reduced response to stimuli.

History of present illness

Weight loss in the last 7 d and low-quantity micturition in the last 24 h were reported.

History of past illness

In the first months of life the patient presented three episodes of upper respiratory tract infections.

Personal and family history

Neonatal screening for cystic fibrosis, hypothyroidism, and phenylketonuria were normal. She was assuming about 400 mL/d of milk. With the exception of 400 IU/d of Vitamin D, no other medications were administered.

Physical examination

She showed slightly dry mucous membranes, tachycardia (140 beats/min) and refill time of about 2 s. Fever was absent as such as vomiting or diarrhea.

Laboratory examinations

Urinalysis did not reveal any abnormality. Serum chemistry was as follows: Venous pH 7.5, bicarbonate 35.1 mmol/L, sodium 135 mEq/L, potassium 2.6 mEq/L, chloride 86 mEq/L, creatinine 0.31 mg/dL, calcium 10.7 mg/dL, phosphorous 4.3 mg/dL, magnesium 2.2 mEq/L. Aspartate and alanine aminotransferase, γ-Glutamyl-transferase, glycaemia, bilirubin, erythrocyte sedimentation rate, C-reactive protein, procalcitonin, alkaline phosphatase and complete blood count were within normal limits. Urinary calcium/creatinine ratio was 0.02 mg/mg, fractional excretion of sodium (FeNa) 0.7%. Electrocardiography was normal. After 36 h of treatment, clinical conditions of the patient and serum electrolytes improved. Venous pH was 7.44, HCO3- 25.5 mmol/L, Na 142 mEq/L, K 4.5 mEq/L, CL 105 mEq/L. We submitted our patient to sweat test when she became well hydrated with normal acid-base and electrolyte balance. The sweat test showed NaCl in the sweat of 100 mmol/L (normal value < 60 mmol/L). High sweat NaCl values were confirmed at the following sweat test after 2 d (sweat NaCl 87 mmol/L). So, we performed genetics analysis for cystic fibrosis. Molecular diagnosis showed the following heterozygous mutations: G126D and F508del in the gene CFTR (Figure 1). This genotype has been described as cause of mild cases of cystic fibrosis or of atypical forms (better known as CFTR-related disorders)[3].
Figure 1

Molecular diagnosis showed the following heterozygous mutations: G126D and F508del in the gene CFTR. A: Locus of cystic fibrosis transmembrane conductance regulator gene on Chromosome 7q31.2. The figure was created and modified by DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembi Resources; B: Graphic view of cystic fibrosis transmembrane conductance regulator with pathogenic variants of our patient.

Molecular diagnosis showed the following heterozygous mutations: G126D and F508del in the gene CFTR. A: Locus of cystic fibrosis transmembrane conductance regulator gene on Chromosome 7q31.2. The figure was created and modified by DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembi Resources; B: Graphic view of cystic fibrosis transmembrane conductance regulator with pathogenic variants of our patient.

Imaging examinations

Abdomen ultrasonography was normal.

FINAL DIAGNOSIS

Hypokalemic metabolic alkalosis due to cystic fibrosis presenting with Pseudo-Bartter syndrome.

TREATMENT

When patient was admitted intravenous rehydration with a solution containing NaCl 0.9% and glucose 2.5% with the addition of KCL 40 mEq/m2 per day was started. When dehydration status and hypokalemic metabolic alkalosis was resolved this infusion was stopped.

OUTCOME AND FOLLOW-UP

Gene mutation analysis identified two heterozygous mutations of the CFTR gene: G126D and F508del. This genotype has been described as cause of mild cases of cystic fibrosis or of atypical forms (better known as CFTR-related disorders)[3]. The variable phenotype of patient affected by CFTR-Related disorders makes very complicated the genetic counseling. A regular clinical evaluation is necessary because CF symptoms may appear later[1]. She will undergo follow up visits at 3, 6, 12 mo after the diagnosis and yearly thereafter, because the atypical form (or CFTR-related disorders) could get worse over time. Proper immunization and influenza vaccination were recommended[4].

DISCUSSION

The main causes of metabolic alkalosis are shown in the Table 1[5-8]. Our patient had no signs of gastro-intestinal losses neither assumed any drug or too much calcium and absorbable alkali. Therefore, possible causes were or skin (due to cystic fibrosis) or renal (due mainly to BS) losses. However, our patient recovered too promptly compared with a dehydrated patient with BS[9,10]. Moreover, FeNa was < 1% demonstrating extra-renal losses of sodium (Table 2)[11] and increasing the suspect of cystic fibrosis. In the cystic fibrosis, just chloride depletion (in our case through sweating) is the main cause of electrolyte abnormalities. Physical activity, fever, and heat exposure can determinate an excessive sweat production that causes an extracellular fluid volume and chloride depletion.
Table 1

Main causes of metabolic alkalosis (modified from references[5-8])

Main causes of metabolic alkalosis
Chloride depletion syndromes
Gastric losses (vomiting, nasogastric tube)
Intestinal losses (congenital chloridrorrhea, villous adenomas)
Kidney losses (loop or thiazide diuretics)
Skin losses (cystic fibrosis)
Potassium depletion syndromes
Gastrointestinal losses (laxative abuse)
Kidney losses:
    Primary hyperaldosteronism (11β-HSDH deficit, licorice, Liddle syndrome);
    Secondary hyperaldosteronism (renovascular or malignant hypertension, hemangiopericytoma, Wilm’s tumor, Bartter and Gitelman syndrome,
    thiazide and loop diuretics, hypercapnia quickly corrected)
Other causes
Repeated blood transfusion containing potassium citrate
Bone metastasis
Enteral nutrition with low chloride
Milk-alkali syndrome

11β-HSDH: 11β-hydroxysteroid-dehydrogenase.

Table 2

Bartter’s syndrome and cystic fibrosis: Differential diagnosis (modified from references[9-18])

Cystic fibrosisBartter’s syndrome
ABEAlkalosisAlkalosis
FeNa+u< 1%> 1%
Na+pl
Cl-pl
Cl-u

ABE: Acid-Basic Equilibria; FeNa+u: Urinary Fractional excretion of sodium; Na+pl: Plasmatic Sodium; Cl-pl: Plasmatic Chloride; Cl-u: Urinary Chloride.

Main causes of metabolic alkalosis (modified from references[5-8]) 11β-HSDH: 11β-hydroxysteroid-dehydrogenase. Bartter’s syndrome and cystic fibrosis: Differential diagnosis (modified from references[9-18]) ABE: Acid-Basic Equilibria; FeNa+u: Urinary Fractional excretion of sodium; Na+pl: Plasmatic Sodium; Cl-pl: Plasmatic Chloride; Cl-u: Urinary Chloride. The extracellular fluid volume depletion leads to a release of antidiuretic hormone with subsequent sodium reduction, and activation of renin-aldosterone system with potassium reduction. Moreover, chloride depletion causes increased renal bicarbonate reabsorption. This mechanism is regulated by a chloridebicarbonate exchanger (pendrin) located on the intercalated cells, sited in cortical collected duct. When chloride depletion occurs, HCO3- secretion is inhibited by insufficient Cl- for anion exchange. In addition, pendrin is reduced in case of potassium depletion. All these mechanisms determine hypokalemic metabolic alkalosis. According to these pathophysiological mechanisms, chloride supplementation, more than sodium and potassium supplementation, is needed to correct the metabolic alkalosis state. The presence of chloride, in fact, increases pendrin activity, with bicarbonate secretion in the lumen of collected duct[12,13]. This kind of clinical and laboratory presentation of CF (known as Pseudo-BS)[14-18], usually, involves children < 2.5 years and is the presenting clinical picture of CF. Episode of vomiting, excessive sweating, heat exposure, fever or respiratory infection could cause a Pseudo-BS, in case of an underlining CF[15,18]. In our case, with the exception of heat exposure, there were no other reasons justifying the dehydration (gastrointestinal fluid losses with diarrhea and/or vomiting, reduction of salt and fluid intake and/or absorption, excessive sweat production for physical activity or fever). For this reason, we performed sweat test in the suspect of cystic fibrosis. Sweat test is the gold standard to diagnose classical or atypical forms of CF[19]. In fact, even with over 1000 mutations in the CFTR gene on chromosome 7 are known and it is possible to find children with cystic fibrosis which do not present identifiable gene mutations[20]. Nevertheless, some mutations could show atypical and very mild clinical manifestations[1]. In these cases, sweat test results can be intermediate or negative (2%) and so other diagnostic tests are indicated, if clinical manifestations persist (i.e., genetic CFTR tests, CFTR functional tests, such as nasal potential difference, intestinal current measurement)[21,22]. Moreover, it is possible that these patients passed the new-born screening because their sufficient pancreatic status[21-24]. So, clinicians must not exclude, a priori, the suspicious of CF in patients with 1 or more clinical manifestations of CF, despite of negative newborn screening results[25-27].

CONCLUSION

In conclusion, with this case presentation we would highlight that the Pseudo-Bartter’s syndrome could be an initial clinical presentation of cystic fibrosis, and that the heat exposure might be a trigger of this condition. When facing a Pseudo-Bartter’s syndrome, cystic fibrosis should not be excluded from differential diagnosis, even if the new-born screening was negative.
  24 in total

1.  Pseudo-Bartter's syndrome in cystic fibrosis.

Authors:  J D Kennedy; R Dinwiddie; C Daman-Willems; M J Dillon; D J Matthew
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

2.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 3.  Approach to metabolic alkalosis.

Authors:  Jennifer T Soifer; Hyung T Kim
Journal:  Emerg Med Clin North Am       Date:  2014-03-14       Impact factor: 2.264

4.  The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis.

Authors:  Christina T Dunn; Mary M Skrypek; Amy L R Powers; Theresa A Laguna
Journal:  Pediatrics       Date:  2011-07-04       Impact factor: 7.124

Review 5.  Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.

Authors:  Joseph L Bobadilla; Milan Macek; Jason P Fine; Philip M Farrell
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

Review 6.  Electrolyte abnormalities in cystic fibrosis: systematic review of the literature.

Authors:  Elisabetta Scurati-Manzoni; Emilio F Fossali; Carlo Agostoni; Enrica Riva; Giacomo D Simonetti; Maura Zanolari-Calderari; Mario G Bianchetti; Sebastiano A G Lava
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

Review 7.  Bartter Syndrome and Gitelman Syndrome.

Authors:  Rosanna Fulchiero; Patricia Seo-Mayer
Journal:  Pediatr Clin North Am       Date:  2019-02       Impact factor: 3.278

8.  Episodic seasonal Pseudo-Bartter syndrome in cystic fibrosis.

Authors:  Brett Kintu; Alex Brightwell
Journal:  Paediatr Respir Rev       Date:  2014-05-10       Impact factor: 2.726

9.  Pseudo-Bartter syndrome in children with cystic fibrosis.

Authors:  Mojgan Faraji-Goodarzi
Journal:  Clin Case Rep       Date:  2019-04-29

Review 10.  Pseudo-Bartter's Syndrome in Patients with Cystic Fibrosis: A Case Series and Review of the Literature.

Authors:  Gordana Vilotijević-Dautović; Vesna Stojanović
Journal:  Srp Arh Celok Lek       Date:  2015 Nov-Dec       Impact factor: 0.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.